Business● Low2h ago · Nov 6, 2026, 4:55 PM
Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Starling Oncology forecasts revenues of $650M-$660M and adjusted EBITDA of $4M-$6M for 2026, with a target of 100% capitated revenue growth in 2027. This outlines the company's financial projections and growth strategy.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business36m agoCalumet targets 200m gallons of SAF in 2028 as it outlines $30m annual MRL lease payments to CMRSeeking Alpha TechBusiness36m agoMach outlines 2027 plan for 2 Oswego rigs and 7 Mancos completions in Q2–Q3 2027 while targeting sub-50% reinvestmentSeeking Alpha TechBusiness36m agoTerawulf outlines $700M annualized run-rate leasing revenue exit for Q1 2027 amid Google-backed Justified financing progressSeeking Alpha TechBusiness45m agoF&G targets $1B-$1.5B in full-year PRT sales while strategic review of Peak Altitude remains activeSeeking Alpha Tech